Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hope they froze the tumor when it was resected.
I hope they froze the tumor when it was resected.
I am still waiting as well. (Mon. night)
I am no expert, but imagine that the FTD numbers are not really the ones we think of when we speak of naked shorting. The FTDs are countable and within the system and therefore of know origin and the responsible party is on the hook should things go wrong. The much bigger problem are those shorts that are totally off the radar screen.
In any case, can someone clarify what happens once these shorts are declared FTDs? Are they immediately forced to cover those shorts by the authorities? Or are they allowed to sit on the books as FTDs without any action to compel setting the books straight? If so, for how long can this go on?
It is very interesting and ironic that it is the mutating of the virus that causes so much trouble in covid and the flu that requires constant annual changes to the virus and yet it is the mutations in the tumor that allows the dcvax vaccine to target the tumor for attack by the immune system.
That is an interesting tidbit.
so what does that mean? they control (or have a stake in) both sides of the street? Thus both CNN, NYT and Fox News report to the same people? etc? Competing BP report to the same people?
Why isn't this a major anti trust issue? Do they really control the companies they have a "stake in"?
That's a fair representation of the current situation. But they are also looking closely at Moderna which is essentially in a position competing with DCVAX. Perhaps if both work in the clinic, they want to buy (control) BOTH Pepsi and Coke.
Yes, that is correct. But the reason he did that was because he was responding to my post. In my post, to keep things simple, I dropped the distinction between treating melanoma and treating GBM, considering them both as a platform based on similar science to harness the immune system. So bear with us for allowing simplicity to trump the actual details, while still providing the overall picture.
I meant, it appears that they are seriously looking at alternatives.
Just read the write up on Eisenkraft on the Cohen Milstein website. "Mr. Eisenkraft was honored by Law360 in 2018 as one of six attorneys under the age of forty in the field of securities whose “professional accomplishments belie their age,” check out his long list of Awards etc.
There are three attorneys (2 partners and 1 associate) all Harvard educated on our case. Need to note that this case is only for NWBO not the investors like us. But they also handle class action for investors - so perhaps that is another shoe yet to drop?
Jessica Kim - Harvard Law - Associate; Michael Eisenkraft - Harvard Law - Partner: Laura Posner - Harvard Law - Partner.
If you check the attorneys who filed the case, you will find at the bottom of the complaint. :
Plaintiff
Northwest Biotherapeutics, Inc.
REPRESENTED BY
Ji Eun Kim
(212) 220-2928
Cohen Milstein Sellers & Toll PLLC
88 Pine St.
14th Floor
New York, NY 10005
ATTORNEY TO BE NOTICED
Laura Helen Posner
(212) 838-7797
Cohen Milstein Sellers & Toll PLLC
88 Pine St.
14th Floor, Ste 14th Floor
New York, NY 10005
ATTORNEY TO BE NOTICED
Michael Benjamin Eisenkraft
(212) 838-7797
Fax: (212) 838-7745
Cohen Milstein Sellers & Toll PLLC
88 Pine St.
14th Floor
New York, NY 10005
ATTORNEY TO BE NOTICED
Thanks Ex.
Why does the SEC not also identify which stocks were being manipulated so the investors in those stocks can consider launching civil suits as well to recoup the money they lost.
And that is because DCVAX is a lysate of the tumor, whereas the MRK vaccine uses an analysis of SELECTED tumor antigens MRNA. both of which are presented to antigen presenting cells (mostly) such as Dendritic Cells.
the Reuters story with many similarities to DCVAX. I have highlighted those phrases below: Note also they have not yet even begun a PIII and also it is MUCH more costly to produce as it take them eight weeks as compared to ONE week for DCVAX and less when we finalize automation.
CHICAGO, Dec 13 (Reuters) - An experimental cancer vaccine from Moderna Inc (MRNA.O) based on the messenger RNA (MRNA) technology used in successful COVID-19 vaccines has been shown to work against melanoma, sending Moderna shares more than 20% higher and driving up of other biotechs working on similar treatments.
A combination of Moderna's personalized cancer vaccine and Merck & Co's (MRK.N) blockbuster immunotherapy Keytruda cut the risk of recurrence or death of the most deadly skin cancer by 44% compared with Keytruda alone in a mid-stage trial, the companies said on Tuesday.
The result was considered a "statistically significant and clinically meaningful improvement," the companies said.
Moderna shares were up nearly 23% at $202.80 on Tuesday, while Merck's shares rose 1%. Shares of BioNTech SE (22UAy.DE), which also has successful mRNA vaccine technology, were up 6%, and tiny Gritstone Bio Inc (GRTS.O), which has a cancer vaccine in development, jumped 20% to $3.09.
The study is the first randomized trial to show that combining mRNA vaccine technology with a drug that revs up the immune response would offer a better result for melanoma patients and potentially for other cancers.
Paul Burton, Moderna's chief medical officer, said in a separate interview that the combination "has the capacity to be a new paradigm in the treatment of cancer."
The ongoing study involved 157 patients with stage III/IV melanoma whose tumors were surgically removed before being treated with either the drug/vaccine combo or Keytruda alone with the aim of delaying disease recurrence.
The combination was generally safe and demonstrated the benefit compared with Keytruda alone after a year of treatment. Serious drug-related side effects occurred in 14.4% of patients who received the combination compared with 10% with Keytruda alone.
A PROMISING FIELD
In October, Merck exercised an option to jointly develop and commercialize the treatment, known as mRNA-4157/V940, sharing costs and any profits equally. Merck and Moderna plan to discuss the results with regulatory authorities and start a large Phase III study in melanoma patients in 2023.
The Merck/Moderna collaboration is one of several combining powerful drugs that unleash the immune system to target cancers with mRNA vaccine technology. They are designed to target highly mutated tumors.
The personalized vaccine works in concert with Merck's Keytruda, a so-called checkpoint inhibitor designed to disable a protein called programmed death 1, or PD-1, that helps tumors to evade the immune system.
To build the vaccine, researchers took samples of patients' tumors and healthy tissue. After analyzing the samples to decode their genetic sequence and isolate mutant proteins associated only with the cancer, that information was used to design a tailor-made cancer vaccine.
When injected into a patient, the patient's cells act as a manufacturing plant, producing perfect copies of the mutations for the immune system to recognize and destroy.
Moderna's personalized vaccine can be made in about eight weeks, a time frame the company eventually hopes to halve, Burton said.
Barr said the companies intend to study the approach in other highly mutated cancers, such as lung cancer. Other such cancers include bladder cancers and some breast cancers.
Moderna mRNA rival BioNTech has several cancer vaccine trials in the works including one with Memorial Sloan Kettering Cancer Center in New York testing a personalized vaccine in combination with Roche's (ROG.S) Tecentriq in patients with pancreatic cancer.
Gritstone is testing a personalized, self-amplifying mRNA vaccine in combination with Bristol Myers Squibb's (BMY.N) immunotherapies Opdivo and Yervoy in a midstage trial in patients with advanced solid tumors.
Experts said the personalized vaccines were among several promising cancer vaccine ideas in the works after many failures in the field.
“In general, I think cancer vaccines are kind of at a tipping point, and there are going to probably be a lot of vaccines coming down the pipeline in the next five years,” said Dr. Mary Lenora Disis, director of the UW Medicine Cancer Vaccine Institute in Seattle.
Although the COVID-19 pandemic demonstrated the speed, ease and safety of mRNA vaccines, they came out of years of cancer vaccine research, Disis said.
Reporting by Julie Steenhuysen in Chicago, Michael Erman in New Jersey and Aditya Samal in Bengaluru; Editing by Caroline Humer, Edwina Gibbs and Bill Berkrot
Our Standards: The Thomson Reuters Trust Principles.
Thanks. Is there also a transcript of the Q&A whose audio has now been dropped?
Lykiri, is it clear from the JAMA article, if the "120 Continued with DCVax-L on recurrence" were all instances of true recurrence, or could some (many) of the crossovers have been cases of pseudo-progression incorrectly taken to be true recurrence?
You are right, but in a more important way you are very wrong. That is to say:
Sure, as you wrote, a retail long such as yourself, when you look back some years from now, whether on Dec7, 2022, the share price was $1.05 or $0.85 will make very little difference if you did not have to sell then. On the other hand for NWBO itself, there was a huge difference because they needed funds for more trials such as combos and Solid cancers, but could not afford to do so because the share price was manipulated to be $0.85 rather than where it should have been (based on all the good news) at $3 to $5 or more, which made it impossible to start these much needed trials in order to get this life saving treatment to those suffering from debilitating cancers!
Egrigious contempt, by flouting a direct court order, (the TRO) can IMO result in jail time like in a criminal case - even in a civil case.
That is why we need our attorneys to get in there with both fists!
Edit: This was meant as a response to Underpar71 - not Sky..
As the manipulation is continuing despite the lawsuit, I think that Laura Posner should broaden the suit to include those MMs who aid the named defendants in the manipulations and also immediately demand a TRO halting all such manipulations upon pain of criminal contempt! The manipulations illegally interferes with the ability of NWBO to raise much needed financing to fund new trials in combo trials and in solid cancers much needed by those who suffer from these horrible diseases. All such manipulations must STOP immediately!
I was once told by one of my brokers some years ago that if you have a margin account, that the contract language allows them to loan out shares even in your cash account. Check with your broker, they all seem to follow different rules (Btw, I am in Canada - could be different in the US).
I do not know, but I speculate it could be either spoofing to cap the SP, or it could be as you state, covering. We will see who wins the battle of $1. I suspect it will break later in the day, as SOJO suggests, if the buying pressure can be maintained.
I think we are seeing the newly revised short tactic as a consequence of the lawsuit for spoofing. They now manipulate to maintain the price (not lower it) - They cap the stock price on good news or expected buying pressure. They have now pretty much successfully flat-lined the share price at $1 for almost the last 2 hours, rather than allow the news of LL presentation last night and of the insider buying to raise the share price. IMO the reason for t his is that in the spoofing case it is "relatively" easy to show damages by the amount of the decrease in the share price. But if the spoofing is done so as to maintain the current price (cap the SP) the there are no obvious damages and they would then have to show what the stock might (should have) have risen to, but for the spoofing action to cap the SP. This is more difficult to prove conclusively - so the manipulators think that despite the court case they will get away with this. what is clearly needed is a much higher buy volume that will storm and overwhelm the spoofers. for this, we may need real news, not just anticipation of the good news likely to come. BUT COME IT WILL!
I agree. Posner wisely went for the low hanging fruit in the lawsuit. It is likely that naked shorting is not as easy to show from the records now available to them. But as you say, may become available through discovery in this case which could then be amended to include the damage done via naked shorting. That may also depend on whether this case is on contingency. If it is, the larger risk to the lawyers of being able to prove a naked shorting case may result in them not following that route on their own dime.
I was wondering the same thing. Upon giving it some thought today, I have a speculative answer that seems to make sense. I have been saying all along that for the most part the heavy manipulation is not from the small fry retail shorts who tag along for the ride to make a few pennies here and there. The meaningful manipulation is coming from big players, biopharma, who are behind the MMs and and use AF hit pieces as a front, a rationale for those who believe his lies, and most of all as a bugle call for the attack to begin. In the face of the good news, the manipulation is costing the manipulators some real money. But it does effectively cap the rise in the SP that would otherwise happen. This is a cost probably on the order of some tens of millions to perhaps even a hundred million dollars that the BP who have many BILLIONS to lose in their cancers treatments for chemo and radiation that are barely helping in GBM and other cancers and cause all sorts of horrible side effects. A second likely motive is even if they do not make DCVAX disappear - it is too late for that after the PIII, TLD and JAMA Article, Sawston snd Flaskworks, they still will try to cap the SP in the hopes of saving tens of BILLIONS in the eventual costs of acquiring NWBO for themselves.
So, IMO, the costs of the manipulation are not a profit center, as most people assume shorting would be, but and expense the BPs are willing to expense in order to accomplish their own future revenues. It's like the delivery man who writes off tens of parking tickets (an illegal activity) as a necessary cost of doing business.
so too here, if we find the illegal spoofing activity continuing (perhaps in a less egregious fashion) despite the law suit and all our eyes fixed clearly on the manipulation, the costs the court may impose, even if large, may be seen by the BPs as a necessary cost of doing business. It is not yet clear to me how the end game here works. With any luck, the manipulation will eventually end if 1) the costs do become to large to be worthwhile, 2) the further egregious activity finally gets a response from the SEC and the DOJ and becomes criminal in nature with actual jail time for the offenders.
I would further add, that from my quick reading of the lawsuit, it only seems to address spoofing. It never so far as I can tell addresses naked shorting. Will they address this further down the road, or will this now become (for the while) the preferred method of manipulation down as the NWBO story continues to unfold. So far, it has not been alleged in court (despite statements by LP and LG out of court) and it is not crystal clear if in fact this happens in huge volume.
Finally as some have suggested, I among them< perhaps other MMs not named in the case are stepping in, so their action will not seem as a direct affront to the court if the named defendants continue with this activity.
Aren't you curious enough to contact them?
What interest rate did they offer you?
Don't think so. As any win from the lawsuit will not be in the "short term." The key short term benefit will be in the MMs being reigned in from their spoofing activity thus allowing even the "short term" increase in the share price from the unrestrained normal market activity. Long term increase was never in doubt.
Because we won't sell at today's "reasonable" price. The only deal to be made is at the very elevated future price.
Unfortunately, not only was the lie being continuously repeated, the accompanying true fact that the shorts were in fact able to continuously force a almost daily small decline in the stock. This was not a lie - but a truth that investors knew all too well. Hopefully that is now at an end with the NWBO lawsuit against Citadel et al.
Ex, it now seems you are saying "when" not "if" That is certainly a step forward.
We want it on page one!
The question is not how many are left. They all are. The point is all the MMs will (hopefully) be on good behavior as they are now fully aware that any egregious activity is being watch and be acted on by counsel. This will be true for MMs not named in this lawsuit as well as those named. Legal shorting will remain an option for all MMs, named or not, but hopefully will not be as effective in capping the shares.
Yes, but not if they settle the case!